MADRID 2026 ESMO congress

4742O

Sacituzumab govitecan (SG) combined with enfortumab vedotin (EV) and zimberelimab (ZIM) in treatment-naive metastatic urothelial cancer (mUC): Interim results from phase 1b TROPHY-U-01 cohort 7

R. Sweis[1], P. Grivas[2], T.B. Powles[3], Y. Loriot[4], I. Duran[5], P. Barthelemy[6], J-L. Lee[7], S.J. Shin[8], A. Necchi[9], A. Recio-Boiles[10], M. Marya[11], J. Waldes[12], E. Harting[13], F. Boateng[14], B.A. McGregor[15]

[1] Medicine, University of Chicago, Chicago, United States of America, [2] Medicine Oncology Department, University of Washington, Seattle, United States of America, [3] Department of Medical Oncology, Barts Cancer Centre, Queen Mary University of London, London, United Kingdom, [4] Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France, [5] Medical Oncology Department, Hospital Universitario Marqués de Valdecilla IDIVAL, Santander, Spain, [6] Medical Oncology Department, Institut de Cancérologie Strasbourg Europe; Hôpital Foch, Strasbourg, France, [7] Oncology Department, Asan Medical Center, Seoul, Republic of Korea, [8] Department of Medical Oncology, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea, [9] Medical Oncology Department, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy, [10] Department of Genitourinary Oncology, University of Arizona Cancer Center, Tucson, United States of America, [11] Department of Medical Oncology, Gilead Sciences, Inc., Foster City, United States of America, [12] Oncology, Gilead Sciences, Inc., Foster City, United States of America, [13] Bimetrics, Gilead Sciences, Inc., Foster City, United States of America, [14] Patient Safety, Gilead Sciences, Inc., Foster City, United States of America[15] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

Background

The mUC treatment landscape is evolving with EV + pembrolizumab as the preferred first-line regimen. SG, a Trop-2–targeting ADC, has shown notable efficacy as monotherapy and when combined with pembrolizumab or EV in pretreated patients with mUC. TROPHY-U-01 (NCT03547973) Cohort 7 is evaluating SG + EV + the PD-1 inhibitor ZIM in participants (pts) with treatment-naive mUC.

Methods

Eligible pts with unresectable locally advanced or mUC and no prior systemic therapy for mUC received SG starting at 7.5 mg/kg + EV 1.25 mg/kg (both on days 1 and 8) and ZIM 360 mg (day 1) every 21 days in a safety lead-in (SLI) phase, followed by dose expansion. Dose-limiting toxicities (DLTs) were SG-related toxicities in SLI pts who completed all cycle 1 dosing and 21-day evaluation period. Primary endpoints were safety, tolerability, and objective response rate (ORR) per investigator. Primary G-CSF prophylaxis from cycle 1 was mandatory.

Results

As of Mar 26, 2026, 21 pts were enrolled (SLI n=13; dose expansion n=8). Median (range) age was 67 (39-83) yrs; 16 were male; 13 had ECOG PS 0. Treatment-emergent adverse events (TEAEs) occurred in 95% of pts (grade ≥3 in 62%). TEAEs led to discontinuation of any drug in 33% of pts (14% SG, 19% EV, 0% ZIM); none led to death; 1 pt died from cancer progression. The most common grade ≥3 TEAEs were fatigue (14%), diarrhea, nausea, maculopapular rash, hypokalemia, peripheral neuropathy, spinal fracture, and febrile neutropenia (10% each). The most common treatment-related serious AEs were diarrhea (10%), abdominal pain, colitis, nausea, neutropenia, febrile neutropenia, and sepsis (5% each). Of 12 DLT-evaluable pts, 1 had a DLT (febrile neutropenia lasting <24h). No additive toxicity was observed with the combination vs the expected toxicity profile of the individual drugs. Based on totality of data, SG 7.5 mg/kg was used for expansion. In 18 efficacy-evaluable pts, ORR was 83% (confirmed 72%), including 3 complete responses. Data from ongoing analyses will be presented.

Conclusions

SG + EV + ZIM showed manageable toxicity and promising activity in mUC, supporting further study of this combination in treatment-naive mUC.

Clinical trial identification

NCT03547973.

Editorial acknowledgement

Writing and editorial assistance were provided by Priya Talluri, MSc, of Parexel, and funded by Gilead Sciences, Inc.

Legal entity responsible for the study

Gilead Sciences, Inc.

Funding

Gilead Sciences, Inc.

Disclosure

R. Sweis: Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Institutional, Local PI: Ascendis, Alentis Therapeutics, BMS, Bayer, Eisai, Genentech/Roche, Immunocore, Merck, Mirati, Moderna, Pyxis Oncology, Xencor, Loxo Oncology, Scholar Rock; Financial Interests, Institutional, Steering Committee Member: Gilead. P. Grivas: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Bristol-Myers Squibb, Merck KGaA, Seattle Genetics, Pfizer, Janssen, Genentech/Roche, Gilead Sciences, Fresenius Kabi, Strata Oncology, Astellas Pharma, AbbVie, Bicycle Therapeutics, Daiichi Sankyo, Replimune, Eli Lilly, Urogen, Foundation Medicine; Financial Interests, Institutional, Local PI: Gilead Sciences, Bristol-Myers Squibb, MSD, Merck KGaA, Acrivon Therapeutics, ALX Oncology, Genentech. T.B. Powles: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol-Myers Squibb, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, MSD; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Roche, Pfizer, MSD, AstraZeneca, Ipsen; Financial Interests, Personal, Other, Sponsorship for Uromigos Podcast: Mashup Ltd; Financial Interests, Institutional, Other, honoraria: Gilead; Financial Interests, Personal, Stocks/Shares: CellCarta; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bristol-Myers Squibb, Exelixis, Ipsen, Merck, MSD, Seattle Genetics, Novartis, Pfizer, Merck Serono, Astellas, Johnson & Johnson, Eisai; Financial Interests, Institutional, Other, Honoraria: Gilead. Y. Loriot: Financial Interests, Personal, Advisory Board: Merck Kga, Pfizer, Gilead, Seattle Genetics, Tahio; Financial Interests, Personal, Other, lectures, advisory boards: MSD, AstraZeneca, Astellas, Janssen; Financial Interests, Personal, Other, lectures, advisory boards: Roche, BMS; Financial Interests, Institutional, Research Grant: Janssen, Sanofi, MSD, Roche, Celsius, Amgen; Financial Interests, Institutional, Steering Committee Member: Janssen; Financial Interests, Steering Committee Member: MSD, Astellas, Gilead/Immunomedics, Tahio; Financial Interests, Personal, Steering Committee Member: Basilea; Financial Interests, Institutional, Local PI: Pfizer, MSD, Janssen, Exelixis, AstraZeneca, Pfizer, Merck Kga, BMS, Astellas, Gilead, Incyte, ORION, TYRA, Lilly, corbus, Innate Pharma; Financial Interests, Institutional, Coordinating PI: Janssen; Financial Interests, Research Grant: Novartis; Non-Financial Interests, Member: ESMO, ASCO, AACR; Non-Financial Interests, Other, scientific committee: ARC. I. Duran: Financial Interests, Personal, Advisory Board, I have served as an advisor for this company in the last two years.: Roche Genentech, MSD, Bristol-Myers Squibb; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by Janssen over the last two years.: Janssen; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by Pfizer over the last two years.: Pfizer; Financial Interests, Personal, Other, I have collaborated in academic projects for Ipsen during the past two years: Ipsen; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by this company over the last two years.: Ipsen, Bristol-Myers Squibb; Financial Interests, Personal, Invited Speaker, I have participated in educational events sponsored by this company and i have received compensation for it: Merck; Financial Interests, Personal, Advisory Board, I have participated in different compensated advisory boards over the last two years.: Astellas; Financial Interests, Personal, Advisory Board, I have collaborated as an advisor for this company over the last two years: Immunomedics, Inc.; Financial Interests, Personal, Invited Speaker, I have participated in educational activities sponsored by this company in the last two years.: Eusa Pharma, MSD; Financial Interests, Personal, Invited Speaker, I have participated in educational activities sponsored by Novartis in the last 2 years.: Novartis; Financial Interests, Personal, Invited Speaker, I have participated in compensated educational activities for this company in the last two years.: Astellas; Financial Interests, Personal, Invited Speaker, I have participated in activities sponsored by this company as a guest speaker: Bayer; Financial Interests, Personal, Other, Bayer has covered expenses related to EAU 2023 and ASCO.GU 2025 including registration, travel and accommodation in both cases: Bayer; Financial Interests, Personal, Other, AstraZeneca has covered the cost of registration, accommodation and traveling related to my attendance of ASCO GU 2024 and ASCO 2025: AstraZeneca; Financial Interests, Personal, Other, Merck has covered the cost related to my attendance to ASCO 2024. (Registration, travel and accommodation): Merck; Financial Interests, Personal, Other, Roche has covered registration and travel expenses related to my attendance to ESMO 2025.: Roche; Financial Interests, Personal, Advisory Board, I have participated in compensated advisory boards for this company during the last two years: Samsung Bioepis; Financial Interests, Personal and Institutional, Research Grant, Roche has funded research in my institution to projects under my coordination.: Roche Genentech; Financial Interests, Personal, Steering Committee Member, I serve as a member of a SC for a trial sponsored by this company.: Immunomedics, Inc.; Financial Interests, Personal and Institutional, Research Grant, AZ has funded research conducted in my institution related to a project where I am the PI.: AstraZeneca; Financial Interests, Institutional, Coordinating PI, I am leading a study (Investigator initiated) that is funded by Gilead and sponsored by the foundation of my department (FUPOCAN). I am the national PI of this study and I dont receive any compensation for this.: Gilead; Non-Financial Interests, Leadership Role, I am the president of an independent cooperative group of GU Oncologist from the north of Spain.: GO NORTE; Non-Financial Interests, Member of Board of Directors, I am member of the Board of directors since 2022: ASEICA; Non-Financial Interests, Member of Board of Directors, GUARD is a GU oncology cooperative group. I am a co-founder and member of the board of directors since 2023: GUARD; Non-Financial Interests, Member of Board of Directors, Grupo Germinal is the testicular cancer spanish group, I am currently part of the board of directors since 2020 and future president of the group starting in November 2025: GRUPO GERMINAL; Non-Financial Interests, Principal Investigator, I am the P.I. of the PRISMA-1 study for which FUPOCAN is the sponsor. This is a multicenter national investigator initiated trial in urothelial cancer running in 10 centres in Spain:

FUPOCAN; Non-Financial Interests, Leadership Role, I have been the CO-CHAIR of the GU-TRACK for ESMO ASIA 2024: ESMO; Non-Financial Interests, Other, I am a member of the International Development and Education Award (IDEA) Steering Group for ASCO: ASCO; Non-Financial Interests, Member, I am a member of the board of directors and co-founder of the spanish patient advocacy group in bladder cancer CANVES.: CANVES. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Coordinating PI: Ipsen. J. Lee: Financial Interests, Personal, Advisory Board: Astellas Korea, AstraZeneca, MSD, Novartis; Financial Interests, Personal, Stocks/Shares: Merck, Johnson & Johnson, Amgen; Financial Interests, Institutional, Local PI: Pfizer, Janssen, Novartis, Bristol-Myers Squibb, Genetech, Roche, AstraZeneca, MSD, Bayer Shering Pharma, GI Innovation, Amgen, Oscotec, Arcus Biosciences, Loxo Oncology, Hanmi Pharmaceutical, Dong-A Pharmaceutical, Pin Therapeutics; Financial Interests, Institutional, Coordinating PI: Celltrion. A. Necchi: Financial Interests, Institutional, Research Grant: Merck, AstraZeneca, Ipsen, BMS, Gilead; Financial Interests, Personal, Steering Committee Member: Janssen, Astellas, AstraZeneca, Merck, Gilead, BMS, Bicycle Therapeutics, Daiichi Sankyo; Financial Interests, Coordinating PI: Incyte, Genenta Sciences; Financial Interests, Personal, Coordinating PI: Catalym; Financial Interests, Personal, Funding: Samsung Bioepis; Non-Financial Interests, Leadership Role: Global society of Rare Genitourinary Tumors (GSRGT). M. Marya: Financial Interests, Personal, Full or part-time Employment, Full time Employee: Gilead Sciences; Financial Interests, Personal, Stocks/Shares, Hold Gilead Science stock as employee: Gilead Sciences. J. Waldes: Financial Interests, Institutional, Full or part-time Employment: Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Exelixis, Gilead Sciences. E. Harting: Financial Interests, Personal, Full or part-time Employment, Employee of Gilead Science: Gilead; Financial Interests, Personal, Stocks/Shares, Hold Gilead Science stock as employee: Gilead Science. F. Boateng: Financial Interests, Personal, Stocks/Shares, Employee stocks: Gilead Sciences. B.A. McGregor: Financial Interests, Personal, Advisory Board: Exelixis, BMS, Dendreon, Astellas, Eisai, Pfizer, Gilead, Arcus, Loxo/Lily, AstraZeneca, Merck, Genmab, Summit Pharmaceuticals, Genentech, Seagen; Financial Interests, Personal, Invited Speaker: EMD Serono; Financial Interests, Institutional, Trial Chair: Pfizer, Exelixis, Exelixis, BMS, Gilead; Financial Interests, Institutional, Local PI: Calithera, Seagen, Aveo; Non-Financial Interests, Member: ASCO. All other authors have declared no conflicts of interest.

© European Society for Medical Oncology